Interim analyses may lead to early stopping when which conditions are met?

• A. Efficacy or safety concerns
• B. Budget constraints
• C. Data quality issues
• D. Investigator turnover

Answer: (A)

Interim analyses are planned checks of accumulating trial data that guide decisions about continuing or stopping a study. They are used to protect participants and resources by stopping early when there is a clear benefit or a clear safety risk. If the interim results show a strong, clinically meaningful treatment effect, it may be ethical to stop the trial early so patients can access the effective treatment sooner. Conversely, if there are troubling safety signals, stopping prevents exposing more participants to potential harm. Budget constraints or issues with data quality and investigator turnover do not reflect a data-driven judgment about the treatment’s effect or safety, so they aren’t the primary reasons for early stopping under typical GCP-practice stopping rules.